Related Experiment Videos
Collagen profile in the transplanted heart
H D Tazelaar1, R E Gay, R A Rowan
1Department of Pathology, Stanford University Medical Center, CA.
Human Pathology
|April 1, 1990
Summary
Interstitial myocardial fibrosis in heart transplants is linked to donor ischemia time and cyclosporine use. Fibrosis may stem from cyclosporine rather than rejection episodes, impacting transplanted heart health.
Area of Science:
- Cardiovascular Research
- Transplantation Immunology
- Pathology
Background:
- Interstitial myocardial fibrosis is a known complication in transplanted hearts.
- Characterizing the collagen profile is crucial for understanding fibrosis development.
Purpose of the Study:
- To confirm interstitial myocardial fibrosis in transplanted hearts.
- To analyze the collagen types (I, III, IV, V) present in transplanted hearts.
- To investigate the relationship between fibrosis, donor ischemia time, rejection episodes, and cyclosporine dosage.
Main Methods:
- Endomyocardial biopsy specimens from 30 heart and 4 heart-lung transplants were analyzed.
- Indirect immunofluorescence techniques were employed to detect collagen types I, III, IV, and V.
- Interstitial collagen deposition was quantitatively scored.
Main Results:
- Increased type I collagen was observed in transplants with longer donor ischemia times (distant vs. on-site donors).
- A trend suggested a positive correlation between cyclosporine dose and collagen types III, IV, and V deposition.
- A negative correlation was found between rejection episodes and cyclosporine dose, as well as collagen types III and IV.
Conclusions:
- The study confirms a mixed collagen profile in transplanted hearts.
- Findings suggest that cyclosporine administration, not necessarily prior rejection episodes, contributes to myocardial fibrosis.
- This highlights the importance of managing immunosuppression to mitigate fibrosis in heart transplant recipients.